SkinBioTherapeutics (SBTX) Competitors

SkinBioTherapeutics (LON:SBTX) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Which has preferable earnings and valuation, SBTX or ARIX?

Arix Bioscience has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SkinBioTherapeutics	£1.56M	34.21	-£3.71M	-£1.63	-14.38
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

Which has more volatility & risk, SBTX or ARIX?

SkinBioTherapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

Does the MarketBeat Community favor SBTX or ARIX?

Arix Bioscience received 35 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. Likewise, 63.57% of users gave Arix Bioscience an outperform vote while only 60.26% of users gave SkinBioTherapeutics an outperform vote.

Company	Underperform	Outperform
SkinBioTherapeutics	Outperform Votes 47 60.26%	Underperform Votes 31 39.74%
Arix Bioscience	Outperform Votes 82 63.57%	Underperform Votes 47 36.43%

Is SBTX or ARIX more profitable?

Arix Bioscience has a net margin of 105.64% compared to SkinBioTherapeutics' net margin of -237.95%. Arix Bioscience's return on equity of 6.41% beat SkinBioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SkinBioTherapeutics	-237.95%	-115.86%	-61.18%
Arix Bioscience	105.64%	6.41%	2.18%

Do institutionals & insiders believe in SBTX or ARIX?

16.6% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 20.4% of SkinBioTherapeutics shares are held by company insiders. Comparatively, 20.7% of Arix Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media prefer SBTX or ARIX?

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.75 beat Arix Bioscience's score of 0.00 indicating that SkinBioTherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
SkinBioTherapeutics	Positive
Arix Bioscience	Neutral

Summary

Arix Bioscience beats SkinBioTherapeutics on 11 of the 13 factors compared between the two stocks.